IFF (IFF) Q2 Revenue Tops Estimates

Core Viewpoint - International Flavors & Fragrances (IFF) reported second-quarter 2025 results that exceeded Wall Street expectations, with revenue of $2.76 billion and adjusted EPS of $1.15, despite declines in both revenue and adjusted operating EBITDA margins compared to the previous year [1][5]. Financial Performance - GAAP revenue for Q2 2025 was $2.76 billion, surpassing the estimate of $2.70 billion but down 4.5% from $2.89 billion in Q2 2024 [2][5]. - Adjusted EPS (non-GAAP) was $1.15, slightly below the $1.16 reported in Q2 2024 and above the $1.12 consensus estimate [2][5]. - Adjusted operating EBITDA was $552 million, with a margin of 20.0%, down from 20.4% in the previous year [2][5]. - The Taste segment reported revenue of $631 million, a 3.4% increase year-over-year [2][6]. Business Overview - IFF specializes in creating compounds for flavors, fragrances, food ingredients, enzymes, and probiotics, serving various markets including food, beverages, personal care, and health [3]. - The company is focusing on innovation and has over 3,400 employees dedicated to research and development [4]. Strategic Initiatives - IFF is undergoing a business realignment strategy, including divesting non-core businesses and restructuring segments to enhance focus on higher-value areas [4][8]. - The company completed the divestiture of its Pharma Solutions business and is also selling its Nitrocellulose business [7][8]. - A $500 million share buyback program was launched, and net debt was reduced to 2.5 times adjusted EBITDA from over 3.9 times in Q1 2025 [9]. Research and Development - R&D spending increased by 5% to $182 million, emphasizing the importance of innovation for long-term growth in key product areas [10]. Future Guidance - For FY2025, IFF forecasts sales between $10.6 billion and $10.9 billion, with adjusted operating EBITDA expected in the range of $2.00 billion to $2.15 billion [11]. - The company anticipates comparable currency-neutral sales growth of 1% to 4% and adjusted operating EBITDA growth of 5% to 10%, with divestitures expected to impact sales growth by about 7% [11].